63 completed. 63 Phase 2, 21 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 63 | Completed 63 |
| Phase 1 | 21 | Completed 21 |
| Phase 3 | 4 | Completed 4 |
Follow Lucentis: new trials by email Literature Review of Lucentis trials Research Report on Lucentis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema Vamikibart, Ranibizumab, Sham Procedure - Diabetic Macular Edema | Phase 2 | Completed | Hoffmann-La Roche | 394 | 2021-12-31 | 2026-05-11 |
| A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema Vamikibart, Ranibizumab, Sham Procedure - Diabetic Macular Edema | Phase 2 | Completed | Hoffmann-La Roche | 187 | 2021-12-17 | 2025-10-16 |
| 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO) 601 1.25mg, Ranibizuman 0.5 mg - Branch Retinal Vein Occlusion | Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 60 | 2021-01-28 | 2025-06-27 |
| 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO) 601 1.25mg, Ranibizuman 0.5 mg - Central Retinal Vein Occlusion | Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 60 | 2021-01-27 | 2025-06-27 |
| Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema LKA651, Lucentis - Diabetic Macular Edema | Phase 2 | Completed | Novartis Pharmaceuticals | 91 | 2019-05-24 | 2024-06-20 |
| Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD ALS-L1023, Ranibizumab, Placebo - Age-Related Macular Degeneration | Phase 2 | Completed | AngioLab, Inc. | 126 | 2018-12-07 | 2022-08-11 |
| A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD OPT-302, ranibizumab, sham intravitreal injection - Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Opthea Limited | 366 | 2017-11-06 | 2021-01-12 |
| ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD) Avacincaptad Pegol, Lucentis - Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Ophthotech Corporation | 64 | 2017-10-11 | 2025-06-10 |
| Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF Ranibizumab Injection [Lucentis] - Exudative Age Related Macular Degeneration | Phase 2 | Completed | Southeast Clinical Research Associates, LLC | 20 | 2017-10-01 | 2020-10-22 |
| Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis - Age-Related Macular Degeneration | Phase 2 | Completed | Santen Inc. | 76 | 2017-07-05 | 2021-07-13 |
| A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema Faricimab, Ranibizumab - Diabetic Macular Edema | Phase 2 | Completed | Hoffmann-La Roche | 229 | 2016-04-27 | 2020-09-25 |
| A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Faricimab, Ranibizumab, Sham Procedure - Choroidal Neovascularization | Phase 2 | Completed | Hoffmann-La Roche | 273 | 2015-08-11 | 2020-11-12 |
| The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates ranibizumab 0.3mg - Diabetic Macular Edema, Hard Lipid Exudates | Phase 1 / Phase 2 | Completed | South Coast Retina Center; Carson, McBeath, Boswell, Inc. | 25 | 2015-08-01 | 2021-07-08 |
| Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration Ranibizumab 0.5mg - Age-related Macular Degeneration | Phase 1 / Phase 2 | Completed | Leonard Feiner, MD, PhD | 4 | 2015-05-01 | 2018-08-28 |
| A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) Avacincaptad Pegol - Idiopathic Polypoidal Choroidal Vasculopathy | Phase 2 | Completed | Ophthotech Corporation | 4 | 2015-03-12 | 2025-03-20 |
| A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) ASP8232, ranibizumab, Placebo - Diabetes Mellitus, Diabetic Macular Edema | Phase 2 | Completed | Astellas Pharma Europe B.V. | 96 | 2015-01-12 | 2024-10-31 |
| Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME Ranibizumab 0.3 mg, Aflibercept 2.0 mg - Diabetic Macular Edema | Phase 2 | Completed | Arshad Khanani | 101 | 2015-01-01 | 2019-04-26 |
| Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. 0.5 mg ranibizumab, Targeted Retinal Photocoagulation (TRP) - Radiation Retinopathy | Phase 2 | Completed | Greater Houston Retina Research | 40 | 2014-09-23 | 2021-03-25 |
| Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration Ranibizumab 0.5mg - Age-related Macular Degeneration | Phase 1 / Phase 2 | Completed | Southern California Desert Retina Consultants, MC | 108 | 2014-09-17 | 2022-08-25 |
| Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity ranibizumab - Retinopathy of Prematurity (ROP) | Phase 2 | Completed | University Hospital Freiburg | 19 | 2014-08-01 | 2017-03-09 |
Showing 20 of 63. Sign in to see all of them.
Macular Degeneration (16) · Macular Edema (7) · Retinal Vein Occlusion (7) · Choroidal Neovascularization (6) · Diabetic Retinopathy (6) · Polypoidal Choroidal Vasculopathy (5) · Diabetes Mellitus (3) · Edema (3) · Wet Macular Degeneration (3) · Pseudoxanthoma Elasticum (2) · Retinal Detachment (2) · Retinal Diseases (2) · Vision Disorders (2) · Vitreous Hemorrhage (2) · Angioid Streaks (1)
Hoffmann-La Roche (4) · Ophthotech Corporation (3) · Arshad Khanani (2) · California Retina Consultants (2) · Jaeb Center for Health Research (2) · Johns Hopkins University (2) · Quark Pharmaceuticals (2) · Southeast Retina Center, Georgia (2) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (2) · University Hospital, Bonn (2) · University of Sao Paulo (2) · Aerpio Therapeutics (1) · AngioLab, Inc. (1) · Astellas Pharma Europe B.V. (1) · Barnes Retina Institute (1)
United States (46) · Canada (5) · Germany (5) · South Korea (5) · Spain (5) · United Kingdom (5) · Israel (4) · Poland (4) · Czechia (3) · Puerto Rico (3) · Argentina (2) · Brazil (2) · China (2) · Hungary (2) · Latvia (2)
Dennis M. Marcus, M.D. (2) · Hendrik PN Scholl, MD, MA (2) · Abdhish Bhavsar, MD (1) · Adam R. Glassman, MS (1) · Allen Ho, MD (1) · Amy C Schefler, MD (1) · Andreas Stahl, MD (1) · Andrew Strong, Ph.D (1) · Arshad Khanani, MD (1) · Arshad M Khanani, MD (1) · Arthur Korotkin, M.D. (1) · Christina J. Flaxel, MD (1) · Dante Pieramici, MD (1) · David Callanan, MD (1)
PMID 30957581, PMID 17367957, PMID 18214740, PMID 20163368, PMID 20417925, PMID 20856107, PMID 20877651, PMID 20885313, PMID 21232078, PMID 21334595, PMID 21681707, PMID 21704964, PMID 21742303, PMID 21915047, PMID 21955635, PMID 22081150, PMID 22357391, PMID 22882007, PMID 22990319, PMID 23187164, PMID 23370902, PMID 23486999, PMID 23544200, PMID 23777441, PMID 24026871, PMID 24326333, PMID 24335454, PMID 24923076, PMID 24923077, PMID 24967201, PMID 24982728, PMID 25001321, PMID 25019269, PMID 25390730, PMID 25633882, PMID 27836430, PMID 29127949, PMID 29309486, PMID 29729809, PMID 30905643, PMID 31388454, PMID 32303499, PMID 32729888, PMID 34201045, PMID 34463842, PMID 36754174, PMID 37422192, PMID 37868796, PMID 38758639, PMID 40522203
2018 (1), U10EY014231 (1), U10EY018817 (1)